If you have been reading about Dihexa and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for lyophilized peptide-like research chemicals. |
| Solubility | Limited in water; soluble in some organic solvents | DMSO is commonly used for stock solutions. |
| Typical storage | -20 °C or below, desiccated, protected from light | Avoid repeated freeze-thaw cycles. |
| Purity assessment | Reverse-phase HPLC with UV detection | Mass spectrometry is often used for identity confirmation. |
| Common document | Certificate of analysis | Batch-specific; does not establish safety or efficacy. |
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
== Career and research == To juggle parenting and research, Masur moved to the new Medical School at Mount Sinai as an Instructor (part-time) in the Department of Physiology and Biophysics in 1968. where the chairman also provided her with a full-time research assistant. Masur continued as a research associate at Columbia University completing her post-doctoral training in cytochemistry. In collaboration with Eric Holtzman she hypothesized that organelle membrane insertion and removal from the cell surface was the basis for hormone induced alteration in cell membrane permeability. Interest in cell-matrix interaction led her to the cornea where she studied the roles of the extracellular matrix, cell-cell interactions and soluble factors in the wound healing process using a corneal stroma model. Masur's laboratory was funded for 35 years by the National Institutes of Health to explore the hormonal control of membrane transport as well as the cellular mechanisms of wound healing. Her lab determined that myofibroblasts and fibroblasts in the cornea are not "terminally differentiated".
In other systems considered non-traditional, droplet-based microfluidic system, magnetic microdroplets can be a facile means of fabrication and control of micro and nanomaterials, sometimes called "robots". These nanostructures are formed of magnetic nanoparticles in microdroplets that have been manipulated into specific structures by an applied magnetic field. Microhelices are a multifunctional application of this technology. Monodisperse droplets containing magnetic nanoparticles are generated and subjected to a magnetic field which organizes the nanoparticles into a helical template that is fabricated in place through photoinduced polymerization. These microhelices were shown to be effective at clearing channels that were blocked with semi-solid composites of fats, oils, and proteins, such as those found in arteries. Microhelices and microparticle clusters in magnetic droplets have been demonstrated to be a means of transport for small (500 μm diameter) microparticles, showing applications in drug delivery as well. Non-spherical microstructures have also been fabricated using magnetic microfluidics, demonstrating the minute control that is available. Among the non-spherical microstructures to be fabricated were graphene oxide microcapsules that could be aspirated and reinflated using a micropipette, while also exhibiting photoresponsive and magnetoresponsive behavior.
=== Common shape codes === General Service/General Lighting Service (GLS) Light emitted in (nearly) all directions. Available either clear or frosted. Types: General (A), elliptical (E), mushroom (M), sign (S), tubular (T) 120 V sizes: A17, 19 and 21 230 V sizes: A55 and 60 High Wattage General Service Lamps greater than 200 watts. Types: Pear-shaped (PS) Decorative lamps used in chandeliers, etc. Smaller candle-sized bulbs may use a smaller socket. Types: candle (B), twisted candle, bent-tip candle (CA & BA), flame (F), globe (G), lantern chimney (H), fancy round (P) 230 V sizes: P45, G95 Reflector (R) Reflective coating inside the bulb directs light forward. Flood types (FL) spread light. Spot types (SP) concentrate the light. Reflector (R) bulbs put approximately double the amount of light (foot-candles) on the front central area as General Service (A) of same wattage. Types: Standard reflector (R), bulged reflector (BR), elliptical reflector (ER), crown-silvered 120 V sizes: R16, 20, 25 and 30 230 V sizes: R50, 63, 80 and 95 Parabolic aluminized reflector (PAR) Parabolic aluminized reflector (PAR) bulbs control light more precisely. They produce about four times the concentrated light intensity of general service (A), and are used in recessed and track lighting. Weatherproof casings are available for outdoor spot and flood fixtures. 120 V sizes: PAR 16, 20, 30, 38, 56 and 64 230 V sizes: PAR 16, 20, 30, 38, 56 and 64 Available in numerous spot and flood beam spreads. Like all light bulbs, the number represents the diameter of the bulb in 1⁄8 of an inch.
=== Lipids === The lipids found in green coffee include: linoleic acid, palmitic acid, oleic acid, stearic acid, arachidic acid, diterpenes, triglycerides, unsaturated long-chain fatty acids, esters, and amides. The total content of lipids in dried green coffee is 11.7–14 g/100 g. Lipids are present on the surface and in the interior matrix of green coffee beans. On the surface, they include derivatives of carboxylic acid-5-hydroxytryptamides with an amide bond to fatty acids (unsaturated C6 to C24) making up to 3% of total lipid content or 1200 to 1400 microgram/g dried green coffee bean. Such compounds form a wax-like cover on the surface of the coffee bean (200–300 mg lipids/100 g dried green coffee bean) protecting the interior matrix against oxidation and insects. Further, such molecules have antioxidative activity due to their chemical structure. Lipids of the interior tissue are triglycerides, linoleic acid (46% of total free lipids), palmitic acid (30% to 35% of total free lipids), and esters. Arabica beans have a higher content of lipids (13.5–17.4 g lipids/100 g dried green coffee beans) than robustas (9.8–10.7 g lipids/100 g dried green coffee beans). The content of diterpenes is about 20% of the lipid fraction. The diterpenes found in green coffee include cafestol, kahweol and 16-O-methylcafestol. Some of these diterpenes have been shown in in vitro experiments to protect liver tissue against chemical oxidation. In coffee oil from green coffee beans the diterpenes are esterified with saturated long chain fatty acids.
The Schengen rules do not require any other procedures; thus, the Schengen states are free to regulate further details on the content of the registration forms, and identity documents which are to be produced, and may also require the persons exempted from registration by Schengen laws to be registered. A Schengen state is also permitted to reinstate border controls with another Schengen country for a short period where there is a serious threat to that state's "public policy or internal security" or when the "control of an external border is no longer ensured due to exceptional circumstances". When such risks arise out of foreseeable events, the state in question must notify the European Commission in advance and consult with other Schengen states. Since the implementation of the Schengen Agreement, this provision has been invoked frequently by member states, especially in response to the European migrant crisis.
Sources: en.wikipedia.org
== External links == VICE In-house Chemist Hamilton Morris on the Dangers of the NBOMe Hallucinogen - VICE - YouTube What Are N-Bombs? (25-I-NBOMe) — Avoid This Psychedelic - Tripsitter Unmasking Fake Acid: The Dangers of 25I-NBOMe Disguised as LSD - Psychedelic Spotlight Dropping the NBOMe... - Alien Insect on Drugs (Andrew Gallimore) - Substack
=== Unknown blood type === Because blood type O negative is compatible with anyone, it is often overused and in short supply. According to the Association for the Advancement of Blood and Biotherapies, the use of this blood should be restricted to persons with O negative blood, as nothing else is compatible with them, and women who might be pregnant and for whom it would be impossible to do blood group testing before giving them emergency treatment. Whenever possible, the AABB recommends that O negative blood be conserved by using blood type testing to identify a less scarce alternative.
== Description == PrRP has 20 amino acids, and is a member of the RFamide peptide family. During the discovery process, PrRP was found to be a ligand for an orphan G-protein coupled receptor (GPR 10). Preliminary in vitro studies showed it to stimulate the secretion of prolactin from lactotropic cells, hence its name. Now, however, the function of PrRP in the brain is understood in terms of negative regulation of appetite. PrRP is produced by noradrenergic neurons A1 and A2 in the solitary nucleus, and also by neurons in the hypothalamus.
=== Before 1873 === Prior to Japan adopting the Gregorian calendar, it used the lunisolar Japanese calendar. The first five years of the era correspond to the following date ranges in the Gregorian calendar:
Sources: en.wikipedia.org
It gained momentum when the USSR sent the first human, Yuri Gagarin, into space with the orbital flight of Vostok 1 on April 12, 1961. These were followed by a string of other firsts achieved by the Soviets over the next few years. Gagarin's flight led US president John F. Kennedy to raise the stakes on May 25, 1961, by asking the US Congress to commit to the goal of "landing a man on the Moon and returning him safely to the Earth" before the end of the decade. Both countries began developing super heavy-lift launch vehicles, with the US successfully deploying the Saturn V, which was large enough to send a three-person orbiter and two-person lander to the Moon. Kennedy's Moon landing goal was achieved in July 1969, with the flight of Apollo 11. The USSR continued to pursue crewed lunar programs to launch and land on the Moon before the US with its N1 rocket but did not succeed, and eventually canceled it to concentrate on Salyut, the first space station program, and the first landings on Venus and on Mars. Meanwhile, the US landed five more Apollo crews on the Moon, and continued exploration of other extraterrestrial bodies robotically. A period of détente followed with the April 1972 agreement on a cooperative Apollo–Soyuz Test Project (ASTP), resulting in the July 1975 rendezvous in Earth orbit of a US astronaut crew with a Soviet cosmonaut crew and joint development of an international docking standard APAS-75. Being considered as the final act of the Space Race by many observers, the competition was however only gradually replaced with cooperation.
=== Cited texts === Borror DJ, Triplehorn CA, Delong DM (1989). Introduction to the Study of Insects (6th ed.). Saunders College Publishing. ISBN 978-0-03-025397-3. Hölldobler B, Wilson EO (1990). The Ants. Harvard University Press. ISBN 978-0-674-04075-5.
Rice (1932–2024), physical chemist Ellen Swallow Richards (1842–1911), industrial and environmental chemist Theodore William Richards (1868–1928), 1914 Nobel Prize in Chemistry Wim Richter (1946–2019), South Africa Jeremias Benjamin Richter (1762–1807), German chemist, first used the term stoichiometry Nikolaus Riehl (1901–1990), German chemist Andrés Manuel del Río (1764–1849), Spanish-Mexican geochemist, discovered vanadium Robert Robinson (1886–1975), British chemist, 1947 Nobel Prize in Chemistry Pierre Jean Robiquet (1780–1840), French chemist, discovered caffeine, alizarin, cantharidin Hillar Rootare (1928–2008), Estonian-American physical chemist Irwin Rose (1926–2015), 2004 Nobel Prize in Chemistry Guillaume-François Rouelle (1703–1770), French chemist Hilaire-Marin Rouelle (1718–1779), French chemist Frank Sherwood Rowland (1927–2012), 1995 Nobel Prize in Chemistry Daniel Rutherford (1749–1819), Scottish chemist Ernest Rutherford (1871–1937), New Zealand born chemist and nuclear physicist. Discovered the proton. Nobel Prize in Chemistry 1908 Leopold Ruzicka (Lavoslav Ružička) (1887–1976), 1939 Nobel Prize in Chemistry
=== Surgery === In severe cases, an endoscopic thoracic sympathectomy procedure can be performed. Here, the nerves that signal the blood vessels of the fingertips to constrict are surgically cut. Microvascular surgery of the affected areas is another possible therapy, but this procedure should be a last resort. A more recent treatment for severe Raynaud's is botulinum toxin. In a 2009 study of 19 patients ranging in age from 15 to 72 years with severe Raynaud's phenomenon, 16 patients (84%) reported pain reduction at rest, 13 patients reported immediate pain relief, and three had gradual pain reduction over 1–2 months. All 13 patients with chronic finger ulcers healed within 60 days. Only 21% of the patients required repeated injections. A 2007 article describes similar improvement in a series of 11 patients. All patients had significant relief of pain.
To start, the resting membrane potential of the Venus flytrap (−120 mV) is lower than animal cells (usually −90 mV to −40 mV). The lower resting potential makes it easier to activate an action potential. Thus, when an insect lands on the trap of the plant, it triggers a hair-like mechanoreceptor. This receptor then activates an action potential that lasts around 1.5 ms. This causes an increase of positive calcium ions into the cell, slightly depolarizing it. However, the flytrap does not close after one trigger. Instead, it requires the activation of two or more hairs. If only one hair is triggered, it disregards the activation as a false positive. Further, the second hair must be activated within a certain time interval (0.75–40 s) for it to register with the first activation. Thus, a buildup of calcium begins and then slowly falls after the first trigger. When the second action potential is fired within the time interval, it reaches the calcium threshold to depolarize the cell, closing the trap on the prey within a fraction of a second. Together with the subsequent release of positive potassium ions the action potential in plants involves an osmotic loss of salt (KCl). Whereas, the animal action potential is osmotically neutral because equal amounts of entering sodium and leaving potassium cancel each other osmotically. The interaction of electrical and osmotic relations in plant cells appears to have arisen from an osmotic function of electrical excitability in a common unicellular ancestors of plants and animals under changing salinity conditions.
Sources: en.wikipedia.org
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.
Reverse-phase HPLC is commonly used to estimate purity, and mass spectrometry helps confirm molecular identity. Certificates of analysis may summarize these results. Independent testing can provide additional verification when standards are unavailable.
In many countries, dihexa is not approved as a medicine and is sold only for research purposes. Regulations differ by jurisdiction, and import or possession rules may apply. Buyers should confirm local legal status before obtaining it.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.